跳至主要内容
临床试验/CTRI/2022/01/039765
CTRI/2022/01/039765已完成未知

A randomized, cross-over, double blind study to determine the glycemic index of 2 test products in healthy subjects by using in-vivo method. - Determine the Glycemic Index of Malt based test products with high fibre in healthy subjects

Hindustan Unilever Limited0 个研究点目标入组 18 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1)Age: 18 to 45 years (both inclusive) at the time of consent.
  • 2)Sex: Male and non-pregnant/non-lactating female.
  • 3)Females of Childbearing potential must have a negative urine pregnancy test performed during screening.
  • 4)Subjects having fasting blood glucose levels <100mg/dL.
  • 5)Subjects having HbA1c level <5.7 %
  • 6)Subjects with Body Mass Index of 18.5 to 22.9 kg/m2 (both inclusive).
  • 7)Subject is in good general health as determined by the Investigator based on medical history and vital signs.
  • 8)Subjects should be willing and able to follow the study protocol to participate in the study.
  • 9)Subject must be able to understand and provide written informed consent to participate in the study.
  • 10)Subject is willing to refrain from vigorous physical exercise during the study period.

排除标准

  • 1)Subject with any known food allergy or intolerance to any food or beverages.
  • 2)Subject taking any medication in the past one week.
  • 3)Subject with presence of any chronic disease or illness in the past three months or any clinically significant on-going chronic medical illness e.g., Congestive cardiac failure, Hepatitis, Hypotensive episodes, etc.
  • 4)Subject with recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 24 hours prior to the study.
  • 5)Subject who has participated in any clinical trial within the past 90 days with blood loss more than 450 mL.
  • 6)Subject on an unusual diet, special diet, for whatever reason e.g., high protein diet, low sodium diet, for two weeks prior to receiving any test food and throughout subjectââ?¬•s participation in the study.
  • 7)Subject who has performed vigorous physical exercise in the morning on dosing day.
  • 8)Female subjects who are pregnant or who are on lactation.
  • 9)Subjects who have tested positive for HIV test.
  • 10)Subjects who have current or recent history (within one year of screening) of alcohol (14 units a week on a regular basis) or other substance abuse.
  • 11)Subjects who are users of Nicotine.
  • 12)Subjects who are currently smoking (or use nicotine containing products) or who have quit smoking (or using nicotine containing products) during the past 3 months.
  • 13)Subjects having history of Hepatitis B or C virus.

研究者

相似试验

进行中(未招募)
1 期
Randomised, Double-Blind, Cross-over Study to Determine the 24-hour FEV1-time Profile of Orally Inhaled BI 1744 CL, delivered with the Respimat® Inhaler, after 3 Weeks of Once Daily (5 mcg [2 actuations of 2,5 mg], 10 mcg [2 actuations of 5 mcg]) or Twice Daily (2 mcg [2 actuations of 1 mcg], 5 mg [2 actuations of 2,5 mcg]) Administration in Patients with Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPD
EUCTR2008-006334-10-NLBoehringer Ingelheim BV48
进行中(未招募)
1 期
Functional MRI study of the central effects of erenumab in patients with episodic migraine.Episodic migraineMedDRA version: 20.0Level: PTClassification code 10027599Term: MigraineSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2018-004875-11-ITOVARTIS FARMA S.P.A.140
招募中
不适用
A Study to Investigate the Effects of Oxygen in Obesity Hypoventilation Syndrome
ACTRN12608000592347Medical Research Institute of New Zealand24
已完成
不适用
A randomized, double-blind, crossover study to examine the effects of concurrent intake of alcohol and test food on cognitive function.
JPRN-UMIN000035722IMEQRD Co., Ltd12
进行中(未招募)
不适用
A randomised, double blind, crossover study to determine the mechanism of action of Gaviscon Advance in Gastro-Oesophageal Reflux Disease (GORD) - Gaviscon AdvanceGastro-oesophageal reflux disease (GORD)
EUCTR2010-019072-68-GBGuy's & St Thomas' NHS Foundation Trust